evoke semaglutide fails to slow cognitive decline in early Alzheimer's The EVOKE trials found that

The Go/NoGo task presented in the current study 51,52 is a perfect example of the latter, given the task by design limited the time the participants had to react to each stimulus, thereby reflecting the differences in sustained attention among participants as differences in accuracy rates

Elife 9 , e57837 (2020)

Semaglutide and other GLP-1 receptor agonists have transformed weight loss outcomes, with clinical trials showing average weight reductions of 15-22% over 68 weeks

Toggling between food-seeking and self-preservation behaviors via hypothalamic response networks

Myhrstad MCW et al

Our support services include: Program Administration Coordinating and synopsizing quarterly DoD Service and Component Program Managers Meetings, working groups, and additional ad hoc program and support meetings for policy development and operations